Back to results
US 2026/0144868 A1Published application
haNK Cetuximab Combinations And Methods
AssigneeNantCell, Inc.
InventorPatrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.
Claims16
A kit of therapeutic compositions for treating a patient having a tumor, comprising:
- an immune therapeutic composition comprising
- (a) a vaccine component comprising a recombinant nucleic acid encoding at least one of brachyury, MUC1, and CEA,
- (b) cetuximab,
- (c) a cytotoxic cell component comprising at least one of a haNK cell, a T-haNK cell, and a T cell, wherein the haNK cell, the t-haNK cell or the T cell is genetically engineered to express a high affinity CD16 variant, and
- (d) ALT803;
- a chemotherapeutic composition comprising a tumor-targeted DNA damaging agent;
- and
- wherein the immune therapeutic composition and the chemotherapeutic composition are provided in quantities sufficient to treat the tumor.
5 more elements
Dependencies are inferred from the claim text.